Literature DB >> 16723607

beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa.

Juliana Gugel, Andrea Dos Santos Pereira, Antônio C C Pignatari, Ana C Gales.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16723607      PMCID： PMC1479105          DOI： 10.1128/AAC.00144-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  7 in total

1.  Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin.

Authors:  Xinying Li; Xilin Zhao; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli.

Authors:  Linda L Marcusson; Sara K Olofsson; Patricia Komp Lindgren; Otto Cars; Diarmaid Hughes
Journal:  J Antimicrob Chemother       Date:  2005-04-28       Impact factor: 5.790

3.  Low correlation between MIC and mutant prevention concentration.

Authors:  Karl Drlica; Xilin Zhao; Joseph M Blondeau; Christine Hesje
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America.

Authors:  A C Gales; K A Gordon; W W Wilke; M A Pfaller; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

Review 5.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

6.  DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.

Authors:  X Zhao; C Xu; J Domagala; K Drlica
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

7.  Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?

Authors:  Gary V Doern; Sandra S Richter; Ashley Miller; Norma Miller; Cassie Rice; Kristopher Heilmann; Susan Beekmann
Journal:  Clin Infect Dis       Date:  2005-06-07       Impact factor: 9.079
  7 in total
  7 in total

Review 1.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

Review 2.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

3.  Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy.

Authors:  Jeffrey J Cies; Wayne S Moore; Susan B Conley; Paul Shea; Adela Enache; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

4.  Pharmacokinetics of Continuous Infusion Meropenem With Concurrent Extracorporeal Life Support and Continuous Renal Replacement Therapy: A Case Report.

Authors:  Jeffrey J Cies; Wayne S Moore; Susan B Conley; Mindy J Dickerman; Christine Small; Dominick Carella; Paul Shea; Jason Parker; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

5.  Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study.

Authors:  Jörn Grensemann; David Busse; Christina König; Kevin Roedl; Walter Jäger; Dominik Jarczak; Stefanie Iwersen-Bergmann; Carolin Manthey; Stefan Kluge; Charlotte Kloft; Valentin Fuhrmann
Journal:  Ann Intensive Care       Date:  2020-04-22       Impact factor: 6.925

6.  Peramivir for Influenza A and B Viral Infections: A Pharmacokinetic Case Series.

Authors:  Jeffrey J Cies; Wayne S Moore; Adela Enache; Arun Chopra
Journal:  Pharmacotherapy       Date:  2019-10-04       Impact factor: 4.705

7.  Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the 'Maximum Tolerable Dose'.

Authors:  Sofie A M Dhaese; Eric A Hoste; Jan J De Waele
Journal:  Antibiotics (Basel)       Date:  2022-07-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.